265 related articles for article (PubMed ID: 25762632)
1. JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.
Qiu H; Jackson AL; Kilgore JE; Zhong Y; Chan LL; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2015 Mar; 6(9):6915-30. PubMed ID: 25762632
[TBL] [Abstract][Full Text] [Related]
2. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
[TBL] [Abstract][Full Text] [Related]
3. Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis.
Zhang MY; Liu SL; Huang WL; Tang DB; Zheng WW; Zhou N; Zhou H; Abudureheman T; Tang ZH; Zhou BS; Duan CW
Med Sci Monit; 2020 Apr; 26():e923411. PubMed ID: 32266878
[TBL] [Abstract][Full Text] [Related]
4. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
[TBL] [Abstract][Full Text] [Related]
5. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
6. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
[TBL] [Abstract][Full Text] [Related]
7. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
8. BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc.
Li N; Yang L; Qi XK; Lin YX; Xie X; He GP; Feng QS; Liu LR; Xie X; Zeng YX; Feng L
Cell Death Dis; 2018 Jul; 9(7):761. PubMed ID: 29988031
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
[TBL] [Abstract][Full Text] [Related]
11. PTTG regulates the metabolic switch of ovarian cancer cells via the c-myc pathway.
Wang X; Duan W; Li X; Liu J; Li D; Ye L; Qian L; Yang A; Xu Q; Liu H; Fu Q; Wu E; Ma Q; Shen X
Oncotarget; 2015 Dec; 6(38):40959-69. PubMed ID: 26516926
[TBL] [Abstract][Full Text] [Related]
12. Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.
Zhu X; Enomoto K; Zhao L; Zhu YJ; Willingham MC; Meltzer P; Qi J; Cheng SY
Clin Cancer Res; 2017 Jan; 23(2):430-440. PubMed ID: 27440272
[TBL] [Abstract][Full Text] [Related]
13. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.
Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L
Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525
[TBL] [Abstract][Full Text] [Related]
14. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma.
Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L
Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803
[TBL] [Abstract][Full Text] [Related]
15. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.
Kumar K; Raza SS; Knab LM; Chow CR; Kwok B; Bentrem DJ; Popovic R; Ebine K; Licht JD; Munshi HG
Sci Rep; 2015 Mar; 5():9489. PubMed ID: 25807524
[TBL] [Abstract][Full Text] [Related]
16. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
17. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
Garcia PL; Miller AL; Kreitzburg KM; Council LN; Gamblin TL; Christein JD; Heslin MJ; Arnoletti JP; Richardson JH; Chen D; Hanna CA; Cramer SL; Yang ES; Qi J; Bradner JE; Yoon KJ
Oncogene; 2016 Feb; 35(7):833-45. PubMed ID: 25961927
[TBL] [Abstract][Full Text] [Related]
18. The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer.
Pang Y; Bai G; Zhao J; Wei X; Li R; Li J; Hu S; Peng L; Liu P; Mao H
J Transl Med; 2022 Jul; 20(1):336. PubMed ID: 35902869
[TBL] [Abstract][Full Text] [Related]
19. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
20. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]